Testing a new cell therapy for active systemic sclerosis
Treatments studied
Part of Skin clinical trials.
This trial tests a new cell therapy (UTAA91) for people with moderate-to-severe systemic sclerosis that hasn't improved with standard treatments. The goal is to see if it can help control the disease when other options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have moderate-to-severe systemic sclerosis that is active and hasn't responded to standard treatments.
- Your expected survival is at least 3 months.
- Your liver, kidney, heart, and lungs are functioning well enough for the trial.
- You do not have a severe mental health condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment, UTAA91 injection, for people with moderate-to-severe systemic sclerosis that hasn't improved with standard therapies. It may offer an option when other treatments have failed or aren't available.
This study tests a new cell therapy called CD19 CAR-T for patients with systemic sclerosis that hasn't improved with standard treatments. The therapy aims to help reduce skin tightening and other symptoms.
This early-phase trial tests GC012F, a type of cell therapy (CAR-T), for treating autoimmune diseases. It aims to see if the treatment can safely calm the immune system and improve symptoms.
This trial tests whether special cells from umbilical cord (UC-MSC) can help treat systemic sclerosis—a disease that causes skin and organ hardening. If you have early systemic sclerosis that hasn't improved enough with standard treatments, this study may offer a new option.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.